Acute Exposure of the Mediobasal Hypothalamus to Amyloid-β25-35 Perturbs Hepatic Glucose Metabolism

Journal of Alzheimer's Disease

Volumn 46, Issue 4, 2015, Pages 843-848

  Arrieta Cruz, Isabel ^a,b   Knight, Colette M ^a   Gutiérrez Juárez, Roger ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b INSTITUTO NACIONAL DE GERIATRÍA   (Mexico)

Author keywords

Alzheimer's disease; amyloid ; diabetes; glucose homeostasis; hyperglycemia; mediobasal hypothalamus

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; GLUCOSE; MESSENGER RNA; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (25-35); GLUCOSE BLOOD LEVEL; PEPTIDE FRAGMENT; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PHOSPHOENOLPYRUVATE CARBOXYKINASE 1 (SOLUBLE) PROTEIN, RAT; SIGNAL PEPTIDE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; IN VIVO STUDY; LIVER METABOLISM; MALE; MEDIOBASAL HYPOTHALAMUS; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; DRUG EFFECTS; GENETICS; GLUCOSE CLAMP TECHNIQUE; LIVER; METABOLISM; SPRAGUE DAWLEY RAT;

AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HYPOTHALAMUS, MIDDLE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; MALE; PEPTIDE FRAGMENTS; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 84938901468     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131865     Document Type: Article

References (45)

1. Craft S, Zallen G, Baker LD, 1992 Glucose and memory in mild senile dementia of the Alzheimer type. J Clin Exp Neuropsychol 14 253 267
2. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC, 2004 Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53 474 481
3. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE, 2012 Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122 1316 1338
4. Ke YD, Delerue F, Gladbach A, Gotz J, Ittner LM, 2009 Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 4 e7917
5. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R, 2010 Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA 107 7036 7041
6. Jolivalt CG, Hurford R, Lee CA, Dumaop W, Rockenstein E, Masliah E, 2010 Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp Neurol 223 422 431
7. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD, 2000 Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283 1571 1577
8. Yamin G, Ono K, Inayathullah M, Teplow DB, 2008 Amyloid beta-protein asbly as a therapeutic target of Alzheimer's disease. Curr Pharm Des 14 3231 3246 sem
9. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW, 1995 Structure-activity analyses of beta-amyloid peptides: Contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem 64 253 265
10. Kaneko I, Morimoto K, Kubo T, 2001 Drastic neuronal loss in vivo by beta-amyloid racemized at Ser(26) residue: Conversion of non-toxic [D-Ser(26)]beta-amyloid 1-40 to toxic and proteinase-resistant fragments. Neuroscience 104 1003 1011
11. Kubo T, Nishimura S, Kumagae Y, Kaneko I, 2002 In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients. J Neurosci Res 70 474 483
12. Kubo T, Kumagae Y, Miller CA, Kaneko I, 2003 Beta-amyloid racemized at the Ser26 residue in the brains of patients with Alzheimer disease: Implications in the pathogenesis of Alzheimer disease. J Neuropathol Exp Neurol 62 248 259
13. Gruden MA, Davudova TB, Malisauskas M, Zamotin VV, Sewell RD, Voskresenskaya NI, Kostanyan IA, Sherstnev VV, Morozova-Roche LA, 2004 Autoimmune responses to amyloid structures of Abeta(25-35) peptide and human lysozyme in the serum of patients with progressive Alzheimer's disease. Dement Geriatr Cogn Disord 18 165 171
14. Millucci L, Ghezzi L, Bernardini G, Santucci A, 2010 Conformations and biological activities of amyloid beta peptide 25-35. Curr Protein Pept Sci 11 54 67
15. Stepanichev MY, Zdobnova IM, Zarubenko II, Lazareva NA, Gulyaeva NV, 2006 Studies of the effects of central administration of beta-amyloid peptide (25-35): Pathomorphological changes in the hippocampus and impairment of spatial memory. Neurosci Behav Physiol 36 101 106
16. Gulyaeva NV, Stepanichev MY, 2010 Abeta(25-35) as proxyholder for amyloidogenic peptides: in vivo evidence. Exp Neurol 222 6 9
17. Kowall NW, McKee AC, Yankner BA, Beal MF, 1992 In vivo neurotoxicity of beta-amyloid [beta(1-40)] and the beta(25-35) fragment. Neurobiol Aging 13 537 542
18. Cuevas E, Lantz SM, Tobon-Velasco JC, Newport GD, Wu Q, Virmani A, Ali SF, Santamaria A, 2011 On the in vivo early toxic properties of A-beta 25-35 peptide in the rat hippocampus: involvement of the receptor-for-advanced glycation-end-products and changes in gene expression. Neurotoxicol Teratol 33 288 296
19. Pena F, Ordaz B, Balleza-Tapia H, Bernal-Pedraza R, Marquez-Ramos A, Carmona-Aparicio L, Giordano M, 2010 Beta-amyloid protein (25-35) disrupts hippocampal network activity: Role of Fyn-kinase. Hippocampus 20 78 96
20. Gengler S, Gault VA, Harriott P, Holscher C, 2007 Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid (25-35) are dependent on stimulation-protocol and genetic background. Exp Brain Res 179 621 630
21. Morgan K, Obici S, Rossetti L, 2004 Hypothalamic responses to long-chain fatty acids are nutritionally regulated. J Biol Chem 279 31139 31148
22. He W, Lam TK, Obici S, Rossetti L, 2006 Molecular disruption of hypothalamic nutrient sensing induces obesity. Nat Neurosci 9 227 233
23. Standaert DG, Lee VM, Greenberg BD, Lowery DE, Trojanowski JQ, 1991 Molecular features of hypothalamic plaques in Alzheimer's disease. Am J Pathol 139 681 691
24. Ogomori K, Kitamoto T, Tateishi J, Sato Y, Suetsugu M, Abe M, 1989 Beta-protein amyloid is widely distributed in the central nervous system of patients with Alzheimer's disease. Am J Pathol 134 243 251
25. Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A, 2001 Sundowning and circadian rhythms in Alzheimer's disease. Am J Psychiatry 158 704 711
26. Gomes S, Martins I, Fonseca AC, Oliveira CR, Resende R, Pereira CM, 2014 Protective effect of leptin and ghrelin against toxicity induced by amyloid-beta oligomers in a hypothalamic cell line. J Neuroendocrinol 26 176 185
27. Su Y, Lam TK, He W, Pocai A, Bryan J, Aguilar-Bryan L, Gutierrez-Juarez R, 2012 Hypothalamic leucine metabolism regulates liver glucose production. Diabetes 61 85 93
28. Limon ID, Diaz A, Mendieta L, Chamorro G, Espinosa B, Zenteno E, Guevara J, 2009 Amyloid-beta(25-35) impairs memory and increases NO in the temporal cortex of rats. Neurosci Res 63 129 137
29. Liu Q, Zhao B, 2004 Nicotine attenuates beta-amyloid peptide-induced neurotoxicity, free radical and calcium accumulation in hippocampal neuronal cultures. Br J Pharmacol 141 746 754
30. Manterola L, Hernando-Rodriguez M, Ruiz A, Apraiz A, Arrizabalaga O, Vellon L, Alberdi E, Cavaliere F, Lacerda HM, Jimenez S, Parada LA, Matute C, Zugaza JL, 2013 1-42 beta-amyloid peptide requires PDK1/nPKC/Rac 1 pathway to induce neuronal death. Transl Psychiatry 3 e219
31. Gutierrez-Juarez R, Obici S, Rossetti L, 2004 Melanocortin-independent effects of leptin on hepatic glucose fluxes. J Biol Chem 279 49704 49715
32. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI, 1992 Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 90 1323 1327
33. Zhang Y, Zhou B, Zhang F, Wu J, Hu Y, Liu Y, Zhai Q, 2012 Amyloid-beta induces hepatic insulin resistance by activating JAK2/STAT3/SOCS-1 signaling pathway. Diabetes 61 1434 1443
34. Samuel VT, Beddow SA, Iwasaki T, Zhang XM, Chu X, Still CD, Gerhard GS, Shulman GI, 2009 Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with Type 2 Diabetes. Proc Natl Acad Sci USA 106 12121 12126
35. Pocai A, Lam TK, Gutierrez-Juarez R, Obici S, Schwartz GJ, Bryan J, Aguilar-Bryan L, Rossetti L, 2005 Hypothalamic K(ATP) channels control hepatic glucose production. Nature 434 1026 1031
36. Kishore P, Boucai L, Zhang K, Li W, Koppaka S, Kehlenbrink S, Schiwek A, Esterson YB, Mehta D, Bursheh S, Su Y, Gutierrez-Juarez R, Muzumdar R, Schwartz GJ, Hawkins M, 2011 Activation of K(ATP) channels suppresses glucose production in humans. J Clin Invest 121 4916 4920
37. Pocai A, Obici S, Schwartz GJ, Rossetti L, 2005 A brain-liver circuit regulates glucose homeostasis. Cell Metab 1 53 61
38. Lam TK, Gutierrez-Juarez R, Pocai A, Rossetti L, 2005 Regulation of blood glucose by hypothalamic pyruvate metabolism. Science 309 943 947
39. Tan S, Ma G, Li Y, Li J, Yao W, Ren X, Liu X, Gao J, 2012 Effects of Abeta(1)(-)(4)(2) on the current of KATP channels in cultured cholinergic neurons. Neurol Res 34 707 713
40. Liu D, Pitta M, Lee JH, Ray B, Lahiri DK, Furukawa K, Mughal M, Jiang H, Villarreal J, Cutler RG, Greig NH, Mattson MP, 2010 The KATP channel activator diazoxide ameliorates amyloid-beta and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease. J Alzheimers Dis 22 443 457
41. Knight CM, Gutierrez-Juarez R, Lam TK, Arrieta-Cruz I, Huang L, Schwartz G, Barzilai N, Rossetti L, 2011 Mediobasal hypothalamic SIRT1 is essential for resveratrol's effects on insulin action in rats. Diabetes 60 2691 2700
42. Huang TC, Lu KT, Wo YY, Wu YJ, Yang YL, 2011 Resveratrol protects rats from Abeta-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. PLoS One 6 e29102
43. Feng X, Liang N, Zhu D, Gao Q, Peng L, Dong H, Yue Q, Liu H, Bao L, Zhang J, Hao J, Gao Y, Yu X, Sun J, 2013 Resveratrol inhibits beta-amyloid-induced neuronal apoptosis through regulation of SIRT1-ROCK1 signaling pathway. PLoS One 8 e59888
44. Frozza RL, Bernardi A, Hoppe JB, Meneghetti AB, Matte A, Battastini AM, Pohlmann AR, Guterres SS, Salbego C, 2013 Neuroprotective effects of resveratrol against Abeta administration in rats are improved by lipid-core nanocapsules. Mol Neurobiol 47 1066 1080
45. Myagkova MA, Gavrilova SI, Lermontova NN, Kalyn YB, Selezneva ND, Zharikov GA, Kolykhalov IV, Abramenko TV, Serkova TP, Bachurin SO, 2001 Autoantibodies to beta-amyloid and neurotransmitters in patients with Alzheimer's disease and senile dementia of the Alzheimer type. Bull Exp Biol Med 131 127 129